A single arm, open-label, Phase IIb study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

Type of Cancer
Ovarian Cancer

Site
Bethesda

Protocol Number
D8488C00001

To Learn More Call
201-510-0910